Key result
In a rabbit LQT3 model, 500 nM AAP10 reduced QT interval and transmural dispersion of repolarization (P<0.001) and prevented early afterdepolarizations, R-on-T extrasystoles, and TdP.
Why the study?
Does antiarrhythmic peptide AAP10 reduce transmural dispersion of repolarization and prevent Torsade de Pointes in a rabbit LQT3 model?
Does antiarrhythmic peptide AAP10 reduce transmural dispersion of repolarization and prevent Torsade de Pointes in a rabbit LQT3 model?
p-value: p=<0.001
Increasing intercellular coupling with the gap junction enhancer AAP10 reduces transmural dispersion of repolarization and prevents Torsade de Pointes in a preclinical LQT3 model.
Supports AAP10 testing in LQT3 models; leaves open clinical translation from rabbit data.
INTRODUCTION: Increased transmural dispersion of repolarization (TDR) contributes importantly to the development of torsades de pointes (TdP) in long QT syndrome (LQTS). Intercellular electrical coupling via gap junctions plays an important role in maintaining TDR in both normal and diseased hearts. This study examined the effects of antiarrhythmic peptide AAP10, a gap junction enhancer, on TDR and induction of TdP in a rabbit LQT3 model. METHODS AND RESULTS: An arterially perfused rabbit left ventricular preparation and sea anemone toxin II (ATX-II, 20 nM) were used to establish a LQT3 model. Transmural ECG as well as action potentials from both endocardium and epicardium were simultaneously recorded. Changes in nonphosphorylated connexin43 (Cx43) were measured by immunoblotting. Compared with the control group, the QT interval, TDR, early afterdepolariztion (EAD), R-on-T extrasystole, and TdP increased sharply with augmented nonphosphorylated Cx43 in the LQT3 group (P < 0.001 for both). Interestingly, compared with the LQT3 group, 500 nM AAP10 reduced QT interval, TDR (P < 0.001 for both), and prevented EAD, R-on-T extrasystole, and TdP (P = 0.003, P = 0.001, P = 0.02) with a parallel decrease in nonphosphorylated Cx43 in the presence of ATX-II (P < 0.001). CONCLUSION: Gap junction enhancer AAP10 is capable of abbreviating the QT interval, reducing TDR, and suppressing TdP in a rabbit LQT3 model probably via its effect by preventing dephosphorylation of Cx43. These data suggest that increasing intercellular coupling may reduce TDR and, therefore, prevent TdP in LQTS.
No takes yet. Share an insight, caveat, or question.
Quan et al. (2007) studied Long QT syndrome (LQT3 model). Antiarrhythmic peptide AAP10 vs. LQT3 control group was evaluated on QT interval, transmural dispersion of repolarization (TDR), early afterdepolarization (EAD), R-on-T extrasystole, and torsades de pointes (TdP) (p=<0.001). In a rabbit LQT3 model, 500 nM AAP10 reduced QT interval and transmural dispersion of repolarization (P<0.001) and prevented early afterdepolarizations, R-on-T extrasystoles, and TdP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: